Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.

[1]  Yoav Ben-Shlomo,et al.  Parkinsonism and Related Disorders , 2016 .

[2]  W. Poewe,et al.  Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. , 2015, Parkinsonism & related disorders.

[3]  V. Fung,et al.  Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results , 2014, Movement disorders : official journal of the Movement Disorder Society.

[4]  H. Fernandez,et al.  Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. , 2015, Journal of Parkinson's disease.

[5]  C. Lundqvist,et al.  Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients , 2014, Journal of Neurology.

[6]  K. Kieburtz,et al.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.

[7]  M. Rizzone,et al.  Prospective assessment of peripheral neuropathy in Duodopa‐treated parkinsonian patients , 2014, Acta neurologica Scandinavica.

[8]  A. Antonini,et al.  Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. , 2014, Parkinsonism & related disorders.

[9]  F. Ehlen,et al.  Neuropathy in Parkinson’s Disease Patients with Intestinal Levodopa Infusion versus Oral Drugs , 2013, PloS one.

[10]  P. Deyn,et al.  Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care , 2013, Journal of Neural Transmission.

[11]  D. Nyholm,et al.  Interim analysis of long‐term intraduodenal levodopa infusion in advanced Parkinson disease , 2012, Acta neurologica Scandinavica.

[12]  I. Forgacs,et al.  Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease: Motor and Nonmotor Effects , 2012, Clinical neuropharmacology.

[13]  D. Nyholm,et al.  Levodopa/carbidopa intestinal gel infusion long‐term therapy in advanced Parkinson’s disease , 2012, European journal of neurology.

[14]  M. Rizzone,et al.  Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study , 2012, Journal of Neurology.

[15]  K. Ray Chaudhuri,et al.  A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK , 2011, Journal of medical economics.

[16]  P. Layer,et al.  Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy , 2010, Movement disorders : official journal of the Movement Disorder Society.

[17]  L. Defebvre,et al.  Intérêts de la stimulation dopaminergique continue par Duodopa ® dans la maladie de Parkinson évoluée : efficacité et tolérance , 2009 .

[18]  L. Defebvre,et al.  [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety]. , 2009, Revue neurologique.

[19]  W. Oertel,et al.  Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease: Practical Aspects and Outcome of Motor and Non-motor Complications , 2008, Clinical neuropharmacology.

[20]  M. Canesi,et al.  Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson’s Disease , 2008, Neurodegenerative Diseases.

[21]  C. Goetz,et al.  Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.

[22]  Laurent Gerbaud,et al.  Impact of the motor complications of Parkinson's disease on the quality of life , 2005, Movement disorders : official journal of the Movement Disorder Society.

[23]  H. Lennernäs,et al.  Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets , 2003, Clinical neuropharmacology.